期刊
DERMATOLOGY AND THERAPY
卷 11, 期 4, 页码 1107-1118出版社
ADIS INT LTD
DOI: 10.1007/s13555-021-00548-2
关键词
Animated visualization; Biologics; Ixekizumab; Meta-analysis
类别
资金
- Eli Lilly and Company (Indianapolis, IN, USA)
Animated visualizations were used to simplify complex data from ixekizumab clinical trials, demonstrating rapid and sustained efficacy of the treatment, providing comparisons with other biologics, and presenting individual patient progression over time.
Introduction Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is an approved treatment for plaque psoriasis. This study aimed to use animated visualizations as a tool to simplify complex data from ixekizumab clinical trials. Methods Animated visualizations were developed to show outcomes from ixekizumab clinical trials and a Bayesian network meta-analysis of 11 approved biologics. The visualizations simultaneously highlighted both aggregate scores and the individual progression of patients over the course of treatment. Results The animations provided key messages and information from the complex data in efficient and scientific ways that were also visually pleasing and simple to understand. The animations highlighted (1) rapid reduction in disease severity from baseline; (2) sustained efficacy of ixekizumab in the treatment of skin and nail psoriasis; (3) side-by-side comparisons of treatment efficacy and clinical improvement across trials; (4) simultaneous visual presentation of individual results with summary response over time; and (5) indirect comparison of relative treatment effects with other biologics based on Bayesian network meta-analysis. Conclusion The rapid and sustained efficacy of ixekizumab in the treatment of psoriasis was demonstrated using multiple dynamic visualizations with different clinical endpoints. Animated visualizations provided a simpler and more comprehensive understanding of complex data than conventional static figures.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据